Full-Time

Director – Scientific Engagement and Professional Societies

Travere Therapeutics

Travere Therapeutics

501-1,000 employees

Develops and commercializes rare-disease therapies

Compensation Overview

$189k - $246k/yr

San Diego, CA, USA

In Person

Category
Biology & Biotech (1)
Requirements
  • Advanced scientific degree (MD, PharmD, PhD)
  • 6+ years Medical Affairs experience in biopharma, ideally within nephrology or rare disease
  • Experience engaging professional societies, guideline bodies, and/or scientific advisory councils
  • Demonstrated success building external partnerships beyond transactional sponsorships
  • Strong cross-functional leadership skills, particularly across Advocacy and Government Affairs
  • Strategic thinker with the ability to identify white-space opportunities and build structured initiatives
Responsibilities
  • Develop and execute a multi-year engagement strategy across major nephrology organizations (e.g., GlomCon, ISGD, ASN, NKF, ERA, KDIGO, ISN and other regional/global societies)
  • Serve as the primary Medical Affairs lead for professional societies and their scientific advisory councils
  • Expand engagement beyond sponsorships & annual congresses to sustained, strategic collaboration
  • Map leadership structures, committees, guideline panels, and advisory boards to identify influence pathways
  • Lead engagement strategy with guideline committees and compendia decision-makers
  • Partner with Ev Gen, Clinical Development, HEOR, and Scientific Communications to align evidence generation and publication timing with guideline cycles
  • Monitor and inform scientific policy statements, consensus documents, and disease frameworks
  • Ensure proactive internal awareness when journals or guideline bodies request external input
  • Ensure professional association collaborative educational efforts reinforce Travere’s disease-state strategy in a compliant manner
  • Lead scientific engagements (e.g., closed door sessions, scientific meetings, advisory boards) with professional association leadership and their scientific advisors, providing subject-matter expertise and strategic direction to ensure consistent, high-impact scientific dialogue
  • Identify and develop collaborative initiatives with professional societies that align with shared priorities, such as implementation science programs, disease awareness initiatives, Glomerular Centers of Excellence models, or education on emerging mechanisms or standards of care
  • Evaluate long-term opportunities that position Travere as a scientific thought partner
  • Partner closely with Government Affairs to monitor evolving nephrology policy landscape, align society engagement with broader health policy initiatives, identify opportunities where scientific collaboration and policy priorities intersect
  • Collaborate with Patient Advocacy to ensure alignment between professional society engagement and patient-led initiatives
  • Facilitate tri-directional alignment across Medical, Advocacy, and Government Affairs when shared initiatives arise
  • Define KPIs that measure impact beyond sponsorship metrics (e.g., guideline inclusion, educational adoption, collaborative project initiation, ecosystem influence)
  • Provide strategic updates and forward-looking recommendations to Therapeutic Area and GMA leadership
  • Establish governance processes for compliant, cross-functional society engagement
Desired Qualifications
  • Demonstrated ability to influence important customers, challenge common perceptions, and implement medical affairs tools to improve patient care and outcomes.
  • Exemplary verbal and written communication skills, including formal presentation skills, and well-developed interpersonal skills.
  • Strong organizational skills with the ability to prioritize and execute against key objectives and deliverables, on time and within budget.
  • Demonstrates the highest ethical standards with strong knowledge of and adherence to applicable regulatory, legal, and compliance requirements.
  • Highly adaptable and resourceful, with the ability to prioritize, manage complexity, and collaborate effectively in a fast-paced, cross-functional environment.
  • Ability to travel up to 40% (ASN, ERA-EDTA, NKF, KOL symposiums, etc.) and manage a rigorous schedule which may require some evening and weekend availability.
  • All positions have an essential job function to perform face-to-face work with colleagues and/or onsite in San Diego. No role is expected to be 100% remote.

Travere Therapeutics develops and commercializes therapies for rare diseases, especially kidney and metabolic disorders. It has commercial products Thiola and Thiola EC for cystinuria and Chenodal for gallstones, with a pipeline that includes sparsentan for focal segmental glomerulosclerosis and IgA nephropathy. The company generates revenue from the sale of its products and supports patients through a dedicated patient assistance program. Its approach centers on identifying and delivering treatments for rare diseases, combining commercialization with ongoing drug development.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

2008

Simplify Jobs

Simplify's Take

What believers are saying

  • FSGS expands FILSPARI to more than 30,000 additional U.S. patients.
  • 2025 FILSPARI sales hit $322 million, up 144%, proving commercial traction.
  • Pegtibatinase HARMONY top-line data in second half 2027 adds pipeline upside.

What critics are saying

  • FILSPARI safety restrictions or REMS burdens can slow adoption and compress growth.
  • Pegtibatinase remains binary; a failed HARMONY readout would remove diversification.
  • Convertible debt refinancing raises dilution risk if shares trade above the $64.90 conversion price.

What makes Travere Therapeutics unique

  • FILSPARI became first FDA-approved FSGS medicine on April 13, 2026.
  • Travere already built nephrology commercial infrastructure through IgA nephropathy FILSPARI launches.
  • Q1 2026 FILSPARI demand reached 993 start forms with over 97% payer access.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Travere Therapeutics who can refer or advise you

Benefits

Health Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Paid Vacation

Wellness Program

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

-3%

2 year growth

-3%
Yahoo Finance
Apr 14th, 2026
Travere's FILSPARI receives FDA approval for FSGS, earns Ligand 9% royalty on sales

Ligand Pharmaceuticals' partner Travere Therapeutics has received FDA approval for FILSPARI (sparsentan) to treat focal segmental glomerulosclerosis (FSGS) in adult and paediatric patients aged eight and older without nephrotic syndrome. FILSPARI becomes the first and only FDA-approved medicine for FSGS, a rare kidney disorder and leading cause of kidney failure. The approval expands FILSPARI beyond IgA nephropathy, where it is already the most commonly prescribed FDA-approved medicine. Ligand is entitled to a 9% royalty on worldwide net sales. Travere estimates the addressable US population exceeds 30,000 individuals with FSGS without nephrotic syndrome. In the Phase 3 DUPLEX Study, FILSPARI demonstrated a statistically significant 48% reduction in proteinuria compared to 27% for irbesartan in patients without nephrotic syndrome.

Yahoo Finance
Apr 13th, 2026
FDA fully approves FILSPARI for FSGS, first treatment for rare kidney disease affecting 30K US patients

Travere Therapeutics announced that the FDA has granted full approval for FILSPARI (sparsentan) to reduce proteinuria in adults and children aged 8 years and older with focal segmental glomerulosclerosis (FSGS) who do not have nephrotic syndrome. FILSPARI is the first and only FDA-approved medicine for FSGS. The approval expands FILSPARI's addressable population to more than 100,000 patients in the US, including over 30,000 with FSGS. The drug is already the most commonly prescribed FDA-approved medicine for IgA nephropathy. In the Phase 3 DUPLEX Study, FILSPARI demonstrated a statistically significant 46% reduction in proteinuria compared to 30% for irbesartan. In patients without nephrotic syndrome specifically, the reduction was 48% versus 27%. The medicine was generally well tolerated across adult and paediatric patients.

The Motley Fool
Jan 25th, 2026
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? | The Motley Fool

This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments.

The Motley Fool
Jan 24th, 2026
Palisades Investment buys $5.3M stake in Travere Therapeutics as shares surge 51%

Palisades Investment Partners initiated a new position in Travere Therapeutics worth $5.26 million, acquiring 137,768 shares in the fourth quarter of 2025, according to an SEC filing. The stake represents 1.99% of the fund's $264.72 million in reportable US equity assets. Travere Therapeutics, a biotechnology company specialising in rare disease therapies, has seen its shares rise 50.89% over the past year to $27.87. The company's revenue surged to $164.9 million in the third quarter, driven by a 155% year-over-year increase in sales of its FILSPARI drug to $90.9 million. The timing of Palisades' investment coincided with FDA review of FILSPARI for potential expanded approval in focal segmental glomerulosclerosis treatments, suggesting confidence in the company's growth prospects.

GlobeNewswire
Jan 13th, 2026
TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm

TVTX ALERT: investigation launched into Travere Therapeutics, Inc., RGRD law attorneys encourage investors and potential witnesses to contact law Firm. SAN DIEGO, Jan. 13, 2026 (GLOBE NEWSWIRE) - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere Therapeutics, Inc. (NASDAQ: TVTX). If you have information that could assist in the Travere investigation or if you are a Travere investor who suffered a loss and would like to learn more, you can provide your information here: You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. THE COMPANY: Travere is a biopharmaceutical company that develops therapies for people living with rare kidney and metabolic diseases in the United States. THE INVESTIGATION: Robbins Geller is investigating whether Travere and certain of its top executives made materially false and/or misleading statements and/or omitted material information regarding Travere's business and operations. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases - more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever - $7.2 billion - in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.